Acer Therapeutics Inc (NASDAQ:ACER) CEO Chris Schelling bought 142,857 shares of Acer Therapeutics stock in a transaction dated Friday, July 24th. The stock was purchased at an average cost of $3.50 per share, for a total transaction of $499,999.50. Following the purchase, the chief executive officer now owns 1,892,857 shares of the company’s stock, valued at approximately $6,624,999.50. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.
Shares of Acer Therapeutics stock opened at $3.93 on Friday. Acer Therapeutics Inc has a 1 year low of $1.08 and a 1 year high of $7.25. The firm’s 50-day moving average is $3.36 and its two-hundred day moving average is $3.25. The stock has a market cap of $40.54 million, a price-to-earnings ratio of -1.51 and a beta of 1.81.
Acer Therapeutics (NASDAQ:ACER) last issued its earnings results on Thursday, May 14th. The biopharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.40) by ($0.09). Research analysts predict that Acer Therapeutics Inc will post -1.38 earnings per share for the current year.
Several equities research analysts have recently weighed in on ACER shares. ValuEngine downgraded shares of Acer Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday. Roth Capital reaffirmed a “buy” rating on shares of Acer Therapeutics in a research note on Monday, June 29th. Needham & Company LLC reaffirmed a “hold” rating on shares of Acer Therapeutics in a research note on Friday, May 15th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Acer Therapeutics in a research note on Tuesday, May 12th. Finally, Zacks Investment Research downgraded shares of Acer Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, July 20th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company. Acer Therapeutics has a consensus rating of “Hold” and an average target price of $6.88.
About Acer Therapeutics
Acer Therapeutics Inc, a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes three clinical-stage candidates: EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; and ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders, maple syrup urine disease, and osanetant for the treatment of various neuroendocrine disorders.
Featured Story: The Structure of a Futures Contract
Receive News & Ratings for Acer Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acer Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.